A First Generation Bisphosphnate Increases Overall Survival in Metastatic Prostate Cancer

A recent report from England, about the first-generation oral bisphosphonate sodium clodronate, claims to improve overall survival in men with metastatic but not localized prostate cancer, according to long-term data from two randomized controlled trials. Among the sample of 278 men all who had metastatic disease starting and who were responding to long-term hormone therapy, [...]

Denosumab Increased Bone Mineral Density in Men With Nonmetastatic Prostate Cancer

Presented at EAU on March 23, 2009 The drug Denosumab has shown itself both easy to tolerate by patients as well highly able to increases bone mineral density (BMD) when compared with placebo in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT). The results of this multi-centre, randomized, double-blind, placebo-controlled, phase 3 study [...]

Continious ADT vs Intermittent – There is a Winner From This Trial

One of the unsettled debates in our advanced prostate cancer world surrounds the issue of continuous vs. intermittent hormone therapy (IHT). Traditionally, hormone therapy was continuous, or once you started you never stopped the treatment. As many of us know, hormone therapy is notorious for damaging the quality of life. Hot flashes, loss of libido, [...]

Is the Honeymoon Over? – A New Report from Scott Goodwin

That is the big question I am dealing with this week. I have been so pleased with my recent success with lowering my PSA, but the last test has reversed the trend. My PSA has shown a drastic rise. It went from just under .60 to almost 2.0 within a two week period! As we [...]

Go to Top